MYO

Company Overview — What Does MYOMO, INC. Do?

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts. MYOMO, INC. (MYO) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Paul R. Gudonis and employs approximately 90 people. With a market capitalization of $26M, MYO is one of the notable companies in the Healthcare sector.

MYOMO, INC. (MYO) Stock Rating — Avoid (April 2026)

As of April 2026, MYOMO, INC. receives a Avoid rating with a composite score of 22.4/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.MYO ranks #4,395 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MYOMO, INC. ranks #821 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MYO Stock Price and 52-Week Range

MYOMO, INC. (MYO) currently trades at $0.69. The stock lost $0.01 (1.4%) in the most recent trading session. The 52-week high for MYO is $5.62, which means the stock is currently trading -87.7% from its annual peak. The 52-week low is $0.63, putting the stock 10.2% above its annual trough. Recent trading volume was 135K shares, suggesting relatively thin trading activity.

Is MYO Overvalued or Undervalued? — Valuation Analysis

MYOMO, INC. (MYO) carries a value factor score of 14/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.29x, versus the sector average of 2.75x. The price-to-sales ratio is 0.67x, compared to 1.66x for the average Healthcare stock.

At current multiples, MYOMO, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

MYOMO, INC. Profitability — ROE, Margins, and Quality Score

MYOMO, INC. (MYO) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -111.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -32.9% versus the sector average of -33.1%.

On a margin basis, MYOMO, INC. reports gross margins of 67.3%, compared to 71.5% for the sector. The operating margin is -32.2% (sector: -66.1%). Net profit margin stands at -32.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 34.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MYO Debt, Balance Sheet, and Financial Health

MYOMO, INC. has a debt-to-equity ratio of 98.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.30x, indicating strong short-term liquidity. Total debt on the balance sheet is $11M. Cash and equivalents stand at $13M.

MYO has a beta of 1.12, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for MYOMO, INC. is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

MYOMO, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, MYOMO, INC. reported revenue of $39M and earnings per share (EPS) of $-0.37. Net income for the quarter was $-13M. Gross margin was 67.3%. Operating income came in at $-13M.

In FY 2025, MYOMO, INC. reported revenue of $41M and earnings per share (EPS) of $-0.37. Net income for the quarter was $-16M. Gross margin was 65.7%. Revenue grew 25.7% year-over-year compared to FY 2024. Operating income came in at $-14M.

In Q3 2025, MYOMO, INC. reported revenue of $10M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-4M. Gross margin was 63.8%. Revenue grew 9.6% year-over-year compared to Q3 2024. Operating income came in at $-4M.

In Q2 2025, MYOMO, INC. reported revenue of $10M and earnings per share (EPS) of $-0.11. Net income for the quarter was $-5M. Gross margin was 62.7%. Revenue grew 28.3% year-over-year compared to Q2 2024. Operating income came in at $-5M.

Over the past 8 quarters, MYOMO, INC. has demonstrated a growth trajectory, with revenue expanding from $8M to $39M. Investors analyzing MYO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MYO Dividend Yield and Income Analysis

MYOMO, INC. (MYO) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MYO Momentum and Technical Analysis Profile

MYOMO, INC. (MYO) has a momentum factor score of 14/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 55/100 reflects moderate short selling activity.

MYO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, MYOMO, INC. (MYO) ranks #821 out of 838 stocks based on the Blank Capital composite score. This places MYO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MYO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MYO vs S&P 500 (SPY) comparison to assess how MYOMO, INC. stacks up against the broader market across all factor dimensions.

MYO Next Earnings Date

No upcoming earnings date has been announced for MYOMO, INC. (MYO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MYO? — Investment Thesis Summary

The quantitative profile for MYOMO, INC. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 14/100 indicates premium valuation. Momentum is weak at 14/100, a headwind for near-term performance. High volatility (stability score 25/100) increases portfolio risk.

In summary, MYOMO, INC. (MYO) earns a Avoid rating with a composite score of 22.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MYO stock.

Related Resources for MYO Investors

Explore more research and tools: MYO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MYO head-to-head with peers: MYO vs AZN, MYO vs SLGL, MYO vs VMD.